← Back to Search

Atypical Antipsychotic

Iloperidone for Parkinson's Disease

Phase 2

Waitlist Available

Research Sponsored by Vanda Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 days and 5 weeks

Awards & highlights

Study Summary

This trial will study the safety and tolerability of the drug iloperidone in elderly patients with Parkinson's disease psychosis.

Eligible Conditions

Parkinson's Disease Psychosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 days and 5 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 days and 5 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 days and 5 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assessment of safety and tolerability of iloperidone in patients with Parkinson's disease psychosis.

Pharmacokinetics of iloperidone and its metabolites following oral treatment with iloperidone.

Reduction in positive symptoms of Parkinson's disease psychosis.

Side effects data

From 2014 Phase 4 trial • 20 Patients • NCT01464229

46%

Dry Mouth

15%

Nausea

15%

Somnolence

15%

Headaches

Cramping

Palpitations

Increased Irritability

100%

80%

60%

40%

20%

Study treatment Arm

Placebo

Iloperidone

Trial Design

2Treatment groups

Experimental Treatment

Group I: Iloperidone (Cohort 2)Experimental Treatment1 Intervention

Group II: Iloperidone (Cohort 1)Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Iloperidone

2015

Completed Phase 4

~1140

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor

61 Previous Clinical Trials

19,401 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA granted sanction to Iloperidone?

"Iloperidone's safety rating is 2 due to its phase two status, which denotes having some data affirming its security but no evidence of efficacy."

Answered by AI

Does this experiment currently seek volunteers?

"According to the current information on clinicaltrials.gov, this trial is actively recruiting patients since its initial posting date of June 1st 2022 and most recent edit date of July 1st 2022."

Answered by AI

How many participants are being considered for inclusion in this clinical investigation?

"Affirmative. Information on clinicaltrials.gov demonstrates that this research program, first published June 1st 2022, is currently open for enrollment. The study requires 24 participants from a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

2022. "A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05344365.